IN THE CLAIMS:

Claim 1 **(previously presented)**: A pyrimidine compound of the Formula I



I

wherein

m is 0, 1, 2 or 3 and

each R^1 group, which may be the same or different, is selected from hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, sulphamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :

$$Q^2\text{-}X^1\text{-}$$

wherein X^1 is a direct bond or is selected from O, S, SO, SO_2, $N(R^4)$, CO, $CH(OR^4)$, $CON(R^4)$, $N(R^4)CO$, $SO_2N(R^4)$, $N(R^4)SO_2$, $OC(R^4)_2$, $SC(R^4)_2$ and $N(R^4)C(R^4)_2$, wherein each R^4 is hydrogen or (1-6C)alkyl, and Q^2 is aryl-(1-6C)alkyl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

or $(R^1)_m$ is (1-3C)alkylenedioxy,

and wherein a single pair of adjacent carbon atoms in a (2-6C)alkylene chain within a R^1 substituent is optionally separated by the insertion of a group selected from O, S, SO, SO_2, $N(R^5)$, CO, $CH(OR^5)$, $CON(R^5)$, $N(R^5)CO$, $SO_2N(R^5)$ and $N(R^5)SO_2$ wherein R^5 is hydrogen or (1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^1 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :

$$-X^2-Q^3$$

wherein X^2 is a direct bond or is selected from O and $N(R^7)$, wherein R^7 is hydrogen or (1-6C)alkyl, and Q^3 is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, and any Q^3 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo or thioxo substituents,

and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino;

R^3 is hydrogen, halogeno or (1-6C)alkyl;

n is 0, 1 or 2 and each R^2 group, which may be the same or different, is selected from hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, (1-6C)alkoxycarbonyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino;

p is 0, 1, 2, 3 or 4; and

Q^1 is aryl or heteroaryl and Q^1 is optionally substituted with 1, 2 or 3 substituents, which may be the same or different, selected from hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or with a (1-3C)alkylenedioxy group, or from a group of the formula :

$$-X^3-Q^4$$

wherein X^3 is a direct bond or is selected from O and $N(R^8)$, wherein R^8 is hydrogen or (1-6C)alkyl, and Q^4 is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, and any Q^4 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino,

and wherein any heterocyclyl group within a substituent on Q^1 optionally bears 1 or 2 oxo or thioxo substituents,

and wherein a single pair of adjacent carbon atoms in a (2-6C)alkylene chain within a Q^1 substituent is optionally separated by the insertion of a group selected from O, S, SO, SO_2, $N(R^9)$, CO, $CH(OR^9)$, $CON(R^9)$, $N(R^9)CO$, $SO_2N(R^9)$ and $N(R^9)SO_2$ wherein R^9 is hydrogen or (1-6C)alkyl,

and wherein any CH_2 or CH_3 group within a Q^1 group optionally bears on each said CH_2 or CH_3 group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-

6C)alkoxy, (1-6C)alkylthio,
(1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,
(1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,
(2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl,
(1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino;
or a pharmaceutically-acceptable salt or in-vivo-cleavable ester formed from an available carboxy group thereof.

Claim 2 **(previously presented)**: A pyrimidine compound of the Formula I according to claim 1 wherein

m is 0, 1, 2 or 3, and each R^1 group, which may be the same or different, is selected from hydroxy, fluoro, chloro, bromo, trifluoromethyl, amino, carbamoyl, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, methylthio, methylsulphinyl, methylsulphonyl, methylamino, ethylamino, propylamino, isopropylamino, butylamino, allylamino, propargylamino, dimethylamino, diethylamino, dipropylamino, N-allyl-N-methylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl and acetamido, or from a group of the formula :

$$Q^2\text{-}X^1\text{-}$$

wherein X^1 is a direct bond or is selected from O, NH and N(Me) and Q^2 is benzyl, 2-furylmethyl, 3-furylmethyl, 2-thienylmethyl, 3-thienylmethyl, 1-imidazolylmethyl, 2-imidazolylmethyl, 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl, 4-imidazol-1-ylbutyl, 2-oxazolylmethyl, 4-oxazolylmethyl, 5-oxazolylmethyl, 2-thiazolylmethyl, 4-thiazolylmethyl, 5-thiazolylmethyl, 1,2,3-triazol-1-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, 3-(1,2,3-triazol-1-yl)propyl, 1,2,4-triazol-1-ylmethyl, 2-(1,2,4-triazol-1-yl)ethyl, 3-(1,2,4-triazol-1-yl)propyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-pyrid-2-ylethyl, 2-pyrid-3-ylethyl, 2-pyrid-4-ylethyl, 3-pyrid-2-ylpropyl,
3-pyrid-3-ylpropyl, 3-pyrid-4-ylpropyl, pyrrolidin-1-yl, pyrrolidin-2-yl,

pyrrolidin-3-yl, morpholino, tetrahydro-4H-1,4-thiazin-4-yl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-1-yl, homopiperidin-2-yl, homopiperidin-3-yl, homopiperidin-4-yl, piperazin-1-yl, homopiperazin-1-yl, pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, pyrrolidin-3-ylmethyl, 2-pyrrolidin-3-ylethyl, 3-pyrrolidin-3-ylpropyl, imidazolidin-1-ylmethyl, 2-imidazolidin-1-ylethyl, 3-imidazolidin-1-ylpropyl, imidazolidin-2-ylmethyl, 2-imidazolidin-2-ylethyl, 3-imidazolidin-2-ylpropyl, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl, morpholin-2-ylmethyl, 2-morpholin-2-ylethyl, 3-morpholin-2-ylpropyl, morpholin-3-ylmethyl, 2-morpholin-3-ylethyl, 3-morpholin-3-ylpropyl, tetrahydro-4H-1,4-thiazin-4-ylmethyl, 2-(tetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(tetrahydro-4H-1,4-thiazin-4-yl)propyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylmethyl, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-2-ylmethyl, 2-piperidin-2-ylethyl,
3-piperidin-2-ylpropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, 3-piperidin-3-ylpropyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 3-piperidin-4-ylpropyl, homopiperidin-1-ylmethyl, 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, homopiperidin-2-ylmethyl, 2-homopiperidin-2-ylethyl, 3-homopiperidin-2-ylpropyl, homopiperidin-3-ylmethyl, 2-homopiperidin-3-ylethyl, 3-homopiperidin-3-ylpropyl, homopiperidin-4-ylmethyl, 2-homopiperidin-4-ylethyl, 3-homopiperidin-4-ylpropyl,
piperazin-1-ylmethyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl, piperazin-2-ylmethyl, 2-piperazin-2-ylethyl, 3-piperazin-2-ylpropyl, homopiperazin-1-ylmethyl, 2-homopiperazin-1-ylethyl, 3-homopiperazin-1-ylpropyl, homopiperazin-2-ylmethyl, 2-homopiperazin-2-ylethyl or 3-homopiperazin-2-ylpropyl,

and wherein a single pair of adjacent carbon atoms in a (2-6C)alkylene chain within a R^1 substituent is optionally separated by the insertion of a group selected from O and NH,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^1 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from hydroxy, fluoro, chloro, trifluoromethyl, amino, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy propoxy, isopropoxy, methoxycarbonyl, ethoxycarbonyl and tert-butoxycarbonyl,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo substituents,

and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group 1 or 2 methyl substituents or a substituent selected from hydroxy, amino, methoxy, ethoxy, methylsulphonyl, methylamino, ethylamino, dimethylamino and diethylamino;

each of n and p is 0;

R^3 is hydrogen or methyl; and

Q^1 is phenyl, 2-furyl, 2-thienyl, 4-oxazolyl, 5-isoxazolyl, 2- or 4-imidazolyl, 3- or 4-pyrazolyl, 4-thiazolyl, 5-isothiazolyl, 2-, 3- or 4-pyridyl, 4-pyridazinyl, 4- or 5-pyrimidinyl, 2- or 6-benzofuranyl, 2- or 6-indolyl, 2- or 6-benzothiophenyl, 2- or 6-quinolyl or 2- or 4-dibenzofuranyl which optionally bears 1, 2 or 3 substituents, , which may be the same or different, selected from hydroxy, fluoro, chloro, bromo, trifluoromethyl, cyano, amino, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, diethylamino, dipropylamino, N-ethyl-N-methylamino, N-methyl-N-propylamino, acetamido, N-methylacetamido, methanesulphonylamino, ethanesulphonylamino, N-methylmethanesulphonylamino, 1-azetidinyl, 3-pyrrolin-1-yl, 1-pyrrolidinyl, morpholino, tetrahydro-4H-1,4-thiazin-4-yl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, 1-piperidinyl, 1-homopiperidinyl, 1-piperazinyl and 1-homopiperazinyl, or from a group of the formula :

$$-X^3-Q^4$$

wherein X^3 is a direct bond or is selected from O, NH and N(Me) and Q^4 is phenyl, 2- or 3-furyl, 2- or 3-thienyl, 1- or 2-imidazolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 2-, 3- or 4-pyridyl, 3- or 4-pyridazinyl, 2- or 4-pyrimidinyl or 2-pyrazinyl, and any Q^4 group optionally bears 1 or 2 substituents, which may be

the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, hydroxy, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino and diethylamino,

and wherein any heterocyclyl group within Q^1 optionally bears 1 or 2 oxo substituents,

and wherein any CH_2 or CH_3 group within a Q^1 group optionally bears on each said CH_2 or CH_3 group 1 or 2 methyl substituents or a substituent selected from hydroxy, amino, methoxy, ethoxy, methylamino, ethylamino, dimethylamino and diethylamino;

or a pharmaceutically acceptable salt or in-vivo-cleavable ester formed from an available carboxy group thereof.

Claim 3 **(previously presented)**: A pyrimidine compound of the Formula I according to claim 1 wherein

m is 0, 1 or 2 and each R^1 group, which may be the same or different, is selected from hydroxy, fluoro, chloro, bromo, trifluoromethyl, amino, carbamoyl, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, methylthio, methylamino, ethylamino, propylamino, isopropylamino, butylamino, allylamino, dimethylamino, diethylamino, dipropylamino, N-allyl-N-methylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl, acetamido, benzyloxy, benzylamino, N-benzyl-N-methylamino, 2-furylmethoxy, 3-furylmethoxy, 2-imidazol-1-ylethylamino, 3-imidazol-1-ylpropylamino, 2-(1,2,4-triazol-1-yl)ethylamino, 3-(1,2,4-triazol-1-yl)propylamino, 2-pyridylmethoxy, 3-pyridylmethoxy, 4-pyridylmethoxy, pyrrolidin-1-yl, pyrrolidin-3-yloxy, pyrrolidin-3-ylamino, N-methyl-N-(3-pyrrolidinyl)amino, morpholino, tetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylamino, piperidin-4-ylamino, N-methyl-N-(3-piperidinyl)amino, N-methyl-N-(4-piperidinyl)amino, homopiperidin-1-yl, homopiperidin-3-yloxy, homopiperidin-4-yloxy, piperazin-1-yl, homopiperazin-1-yl, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-ylethylamino, 3-pyrrolidin-1-ylpropylamino, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy,

pyrrolidin-2-ylmethylamino, 2-pyrrolidin-2-ylethylamino, 3-pyrrolidin-2-ylpropylamino, pyrrolidin-3-ylmethoxy, 2-pyrrolidin-3-ylethoxy, 3-pyrrolidin-3-ylpropoxy, pyrrolidin-3-ylmethylamino, 2-pyrrolidin-3-ylethylamino, 3-pyrrolidin-3-ylpropylamino, 2-imidazolidin-1-ylethoxy, 3-imidazolidin-1-ylpropoxy, imidazolidin-2-ylmethoxy, 2-imidazolidin-2-ylethoxy, 3-imidazolidin-2-ylpropoxy, 2-imidazolidin-1-ylethylamino, 3-imidazolidin-1-ylpropylamino, 2-imidazolidin-2-ylethylamino, 3-imidazolidin-2-ylpropylamino, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-morpholinoethylamino, 3-morpholinopropylamino, morpholin-2-ylmethoxy, 2-morpholin-2-ylethoxy, 3-morpholin-2-ylpropoxy, 2-morpholin-2-ylethylamino, 3-morpholin-2-ylpropylamino, morpholin-3-ylmethoxy, 2-morpholin-3-ylethoxy,
3-morpholin-3-ylpropoxy, 2-morpholin-3-ylethylamino, 3-morpholin-3-ylpropylamino, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-piperidinoethylamino, 3-piperidinopropylamino, piperidin-2-ylmethoxy, 2-piperidin-2-ylethoxy, 3-piperidin-2-ylpropoxy, piperidin-2-ylmethylamino, 2-piperidin-2-ylethylamino, 3-piperidin-2-ylpropylamino, piperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, 3-piperidin-3-ylpropoxy, piperidin-3-ylmethylamino, 2-piperidin-3-ylethylamino, 3-piperidin-3-ylpropylamino, piperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 3-piperidin-4-ylpropoxy, piperidin-4-ylmethylamino, 2-piperidin-4-ylethylamino, 3-piperidin-4-ylpropylamino, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 2-homopiperidin-1-ylethylamino,
3-homopiperidin-1-ylpropylamino, homopiperidin-2-ylmethoxy,
homopiperidin-2-ylmethylamino, homopiperidin-3-ylmethoxy,
homopiperidin-3-ylmethylamino, homopiperidin-4-ylmethoxy,
homopiperidin-4-ylmethylamino, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-piperazin-1-ylethylamino, 3-piperazin-1-ylpropylamino, piperazin-2-ylmethoxy, piperazin-2-ylmethylamino, 2-piperazin-2-ylethoxy, 3-piperazin-2-ylpropoxy, 2-piperazin-2-ylethylamino, 3-piperazin-2-ylpropylamino, 2-homopiperazin-1-ylethoxy, 3-homopiperazin-1-ylpropoxy, 2-homopiperazin-1-ylethylamino, 3-homopiperazin-1-ylpropylamino, homopiperazin-2-ylmethoxy or homopiperazin-2-ylmethylamino,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^1 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from hydroxy, fluoro, chloro, trifluoromethyl, amino, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy propoxy, isopropoxy, methoxycarbonyl, ethoxycarbonyl and tert-butoxycarbonyl,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo substituents,

and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group 1 or 2 methyl substituents or a substituent selected from hydroxy, amino, methoxy, ethoxy, methylsulphonyl, methylamino, ethylamino, dimethylamino and diethylamino;

each of n and p is 0;

R^3 is methyl; and

Q^1 is phenyl or 3- or 4-pyridyl which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from hydroxy, fluoro, chloro, bromo, trifluoromethyl, cyano, amino, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, diethylamino, dipropylamino, N-ethyl-N-methylamino, N-methyl-N-propylamino, acetamido, N-methylacetamido, methanesulphonylamino, ethanesulphonylamino, N-methylmethanesulphonylamino, 1-azetidinyl, 3-pyrrolin-1-yl, 1-pyrrolidinyl, morpholino, 1-piperidinyl, 1-homopiperidinyl, 1-piperazinyl and 1-homopiperazinyl, and wherein any CH_2 or CH_3 group within a Q^1 group optionally bears on each said CH_2 or CH_3 group 1 or 2 methyl substituents or a substituent selected from hydroxy, amino, methoxy, ethoxy, methylamino, ethylamino, dimethylamino and diethylamino;

or a pharmaceutically acceptable salt or in-vivo-cleavable ester formed from an available carboxy group thereof.

Claim 4 **(previously presented)**: A pyrimidine compound of the Formula I according to claim 1 wherein

m is 0, 1 or 2 and each R^1 group, which may be the same or different, is selected from fluoro, chloro, bromo, amino, carbamoyl, methoxy, ethoxy, propoxy, methylthio, methylamino, ethylamino, propylamino, isopropylamino, butylamino, allylamino, dimethylamino, diethylamino, dipropylamino, N-allyl-N-methylamino, pyrrolidin-3-yloxy, morpholino, tetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylamino, piperidin-4-ylamino, N-methyl-N-(3-piperidinyl)amino, N-methyl-N-(4-piperidinyl)amino, homopiperidin-1-yl, homopiperidin-3-yloxy, homopiperidin-4-yloxy, piperazin-1-yl, homopiperazin-1-yl, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-ylethylamino, 3-pyrrolidin-1-ylpropylamino, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, pyrrolidin-2-ylmethylamino, 2-pyrrolidin-2-ylethylamino, 3-pyrrolidin-2-ylpropylamino, pyrrolidin-3-ylmethoxy, 2-pyrrolidin-3-ylethoxy, 3-pyrrolidin-3-ylpropoxy,
pyrrolidin-3-ylmethylamino, 2-pyrrolidin-3-ylethylamino, 3-pyrrolidin-3-ylpropylamino, 2-imidazolidin-1-ylethylamino, 3-imidazolidin-1-ylpropylamino, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-morpholinoethylamino, 3-morpholinopropylamino, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-piperidinoethylamino, 3-piperidinopropylamino, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-piperazin-1-ylethylamino, 3-piperazin-1-ylpropylamino or piperazin-2-ylmethoxy,
and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 substituents, which may be the same or different, selected from hydroxy, fluoro, chloro, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methoxycarbonyl, ethoxycarbonyl and
tert-butoxycarbonyl,
and wherein any heterocyclyl group within a substituent on R^1 optionally bears an oxo substituent,
and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group 1 or 2 methyl substituents or a substituent selected from hydroxy, amino, methylamino, ethylamino, dimethylamino and diethylamino;
each of n and p is 0;

R^3 is methyl; and

Q^1 is phenyl or 4-pyridyl which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, amino, methyl, methoxy, methylamino, ethylamino, dimethylamino, diethylamino, 1-pyrrolidinyl, morpholino, piperidino, 1-homopiperidinyl, 1-piperazinyl and 1-homopiperazinyl, and wherein any CH_2 or CH_3 group within a Q^1 group optionally bears on each said CH_2 or CH_3 group 1 or 2 methyl substituents or a substituent selected from hydroxy, amino, methoxy, ethoxy, methylamino, ethylamino, dimethylamino and diethylamino;

or a pharmaceutically acceptable salt or in-vivo-cleavable ester formed from an available carboxy group thereof.

Claim 5 **(previously presented)**: A pyrimidine compound of the Formula I according to claim 1 wherein

m is 1 or 2 and each R^1 group, which may be the same or different, is selected from chloro, carbamoyl, 3-dimethylaminopropoxy, 3-dimethylamino-2,2-dimethylpropoxy, methylthio, 3-diethylaminopropylamino, 3-dimethylamino-2,2-dimethylpropylamino, 3-dimethylamino-2-hydroxypropylamino, N-isopropylpyrrolidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy, N-ethylpiperidin-3-ylamino, N-methylpiperidin-4-ylamino, N-methyl-N-(N-methylpiperidin-4-yl)amino, 3-pyrrolidin-1-ylpropylamino, N-methylpyrrolidin-2-ylmethoxy, 2-(N-methylpyrrolidin-2-yl)ethoxy, 2-(N-methylpyrrolidin-2-yl)ethylamino, N-methylpiperidin-3-ylmethoxy and N,N'-dimethylpiperazin-2-ylmethoxy;

each of n and p is 0;

R^3 is methyl; and

Q^1 is phenyl which bears 1 or 2 substituents, which may be the same or different, selected from fluoro, trifluoromethyl, dimethylamino, 1-pyrrolidinyl, morpholino, piperidino, 1-homopiperidinyl, 1-piperazinyl and 1-homopiperazinyl, or Q^1 is 4-pyridyl which bears 1 substituent selected from dimethylamino, 1-pyrrolidinyl, morpholino, piperidino, 1-homopiperidinyl, 1-piperazinyl and 1-homopiperazinyl,

or a pharmaceutically acceptable salt or in-vivo-cleavable ester formed from an available carboxy group thereof.

Claim 6 **(previously presented)**: A pyrimidine compound of the Formula I according to claim 1 wherein

m is 0, 1 or 2 and each R^1 group, which may be the same or different, is selected from fluoro, chloro, bromo, amino, carbamoyl, methoxy, ethoxy, propoxy, methylthio, methylamino, ethylamino, propylamino, isopropylamino, butylamino, allylamino, dimethylamino, diethylamino, dipropylamino, N-allyl-N-methylamino, pyrrolidin-3-yloxy, morpholino, tetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylamino, piperidin-4-ylamino, N-methyl-N-(3-piperidinyl)amino, N-methyl-N-(4-piperidinyl)amino, homopiperidin-1-yl, homopiperidin-3-yloxy, homopiperidin-4-yloxy, piperazin-1-yl, homopiperazin-1-yl, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-ylethylamino, 3-pyrrolidin-1-ylpropylamino, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, pyrrolidin-2-ylmethylamino, 2-pyrrolidin-2-ylethylamino, 3-pyrrolidin-2-ylpropylamino, pyrrolidin-3-ylmethoxy, 2-pyrrolidin-3-ylethoxy, 3-pyrrolidin-3-ylpropoxy,
pyrrolidin-3-ylmethylamino, 2-pyrrolidin-3-ylethylamino, 3-pyrrolidin-3-ylpropylamino, 2-imidazolidin-1-ylethylamino, 3-imidazolidin-1-ylpropylamino, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-morpholinoethylamino, 3-morpholinopropylamino, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-piperidinoethylamino, 3-piperidinopropylamino, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-piperazin-1-ylethylamino, 3-piperazin-1-ylpropylamino or piperazin-2-ylmethoxy,
and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 substituents, which may be the same or different, selected from hydroxy, fluoro, chloro, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methoxycarbonyl, ethoxycarbonyl and tert-butoxycarbonyl,
and wherein any heterocyclyl group within a substituent on R^1 optionally bears an oxo substituent,

and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group 1 or 2 methyl substituents or a substituent selected from hydroxy, amino, methylamino, ethylamino, dimethylamino and diethylamino;

each of n and p is 0;

R^3 is methyl; and

Q^1 is 4-dibenzofuranyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, amino, methyl, methoxy, methylamino, ethylamino, dimethylamino and diethylamino;

or a pharmaceutically acceptable salt or in-vivo-cleavable ester formed from an available carboxy group thereof.

Claim 7 **(previously presented)**: A pyrimidine compound of the Formula I according to claim 1 wherein

m is 1 and the R^1 group is selected from chloro, carbamoyl, methoxy, ethoxy, 3-dimethylaminopropoxy, 3-dimethylamino-2,2-dimethylpropoxy, methylthio, N-isopropylpyrrolidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy, N-ethylpiperidin-4-yloxy, N-propylpiperidin-4-yloxy, N-methylpyrrolidin-2-ylmethoxy, 2-(N-methylpyrrolidin-2-yl)ethoxy, N-methylpiperidin-3-ylmethoxy and N,N'-dimethylpiperazin-2-ylmethoxy;

each of n and p is 0;

R^3 is methyl; and

Q^1 is 4-dibenzofuranyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl and dimethylamino,

or a pharmaceutically acceptable salt or in-vivo-cleavable ester formed from an available carboxy group thereof.

Claim 8 **(previously presented)**: A pyrimidine compound of the Formula I according to claim 1 selected from :-

6-carbamoyl-2-chloro-4-[5-(3-fluoro-5-morpholinobenzamido)-2-methylanilino]pyrimidine,

4-[5-(3-fluoro-5-morpholinobenzamido)-2-methylanilino]-2-methylthiopyrimidine,

2-chloro-4-[2-methyl-5-(2-morpholinopyrid-4-ylcarbonylamino)anilino]pyrimidine,

4-[2-methyl-5-(2-morpholinopyrid-4-ylcarbonylamino)anilino]-2-(N-methylpiperidin-4-yloxy)pyrimidine,

2-(3-dimethylaminopropoxy)-4-[2-methyl-5-(2-morpholinopyrid-4-ylcarbonylamino)anilino]pyrimidine,

2-(3-dimethylamino-2,2-dimethylpropoxy)-4-[2-methyl-5-(2-morpholinopyrid-4-ylcarbonylamino)anilino]pyrimidine,

4-[2-methyl-5-(2-morpholinopyrid-4-ylcarbonylamino)anilino]-2-(N-methylpiperidin-3-ylmethoxy)pyrimidine,

2-[N-methyl-N-(N-methylpiperidin-4-yl)amino]-4-[2-methyl-5-(2-morpholinopyrid-4-ylcarbonylamino)anilino]pyrimidine,

4-[2-methyl-5-(2-morpholinopyrid-4-ylcarbonylamino)anilino]-2-[2-(N-methylpyrrolidin-2-yl)ethylamino]pyrimidine,

2-(3-dimethylamino-2,2-dimethylpropoxy)-4-[5-(3-fluoro-5-morpholinobenzamido)-2-methylanilino]pyrimidine,

4-[5-(3-fluoro-5-morpholinobenzamido)-2-methylanilino]-2-(N-methylpiperidin-4-yloxy)pyrimidine,

4-[5-(3-fluoro-5-morpholinobenzamido)-2-methylanilino]-2-(N-propylpiperidin-4-yloxy)pyrimidine,

4-[5-(4-dibenzofuranylcarbonylamino)-2-methylanilino]-2-(N-methylpiperidin-4-yloxy)pyrimidine and

4-[5-(4-dibenzofuranylcarbonylamino)-2-methylanilino]-2-(3-dimethylamino-2,2-dimethylpropoxy)pyrimidine;

or a pharmaceutically acceptable salt or in-vivo-cleavable ester formed from an available carboxy group thereof.

Claim 9 **(previously presented)**: A process for preparing a pyrimidine compound of the Formula I, or a pharmaceutically-acceptable salt or in-vivo-cleavable ester formed from an available carboxy group thereof, according to claim 1:-

(a) reacting an aniline of the Formula II



II

with an acid of the Formula III, or a reactive derivative thereof,



III

under standard amide bond forming conditions, wherein variable groups are as defined in claim 1 and wherein any functional groups are protected if necessary;

(b) the reaction of an activated heteroaryl compound of the Formula V



V

wherein L is a displaceable group, with an aniline of the Formula VII



VII

wherein variable groups are as defined in claim 1 and wherein any functional group is protected if necessary;

(c) for a compound of the Formula I, or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof, wherein R^1 or a substituent on Q^1 is an amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, substituted (1-6C)alkylamino, substituted di-[(1-6C)alkyl]amino, a N-linked heterocyclyl substituent or a heterocyclylamino substituent, the reaction of an appropriate amine with a pyrimidine compound of the Formula I wherein R^1 or a substituent on Q^1 as appropriate is a suitable displaceable group and wherein other

variable groups are as defined in claim 1 and wherein any functional group is protected if necessary;

(d) for a compound of the Formula I, or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof, wherein R^1 or a substituent on Q^1 is a (1-6C)alkoxy or substituted (1-6C)alkoxy substituent or a heterocyclyloxy substituent, the reaction of an appropriate alcohol with a pyrimidine compound of the Formula I wherein R^1 or a substituent on Q^1 as appropriate is a suitable displaceable group and wherein other variable groups are as defined in claim 1 and wherein any functional group is protected if necessary;

(e) for a compound of the Formula I, or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof, wherein m is 0, the cleavage of a compound of the Formula I, wherein m is 1, 2 or 3 and each R^1 substituent is a halogeno group and wherein other variable groups are as defined in claim 1 and wherein any functional group is protected if necessary;

(f) for a compound of the Formula I, or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof, wherein R^1 or Q^1 contains a (1-6C)alkoxy or substituted (1-6C)alkoxy group or a (1-6C)alkylamino or substituted (1-6C)alkylamino group, the alkylation of a pyrimidine compound of the Formula I wherein R^1 or Q^1 contains a hydroxy group or a primary or secondary amino group as appropriate, and wherein other variable groups are as defined in claim 1 and wherein any functional group is protected if necessary;

(g) for a compound of the Formula I, or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof, wherein R^1 is a hydroxy group, the cleavage of a compound of the Formula I, wherein R^1 is a halogeno group and wherein other variable groups are as defined in claim 1 and wherein any functional group is protected if necessary; or

(h) for a compound of the Formula I, or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof, wherein R^1 is a (1-6C)alkylsulphinyl or (1-6C)alkylsulphonyl group, the oxidation of a compound of the Formula I, wherein R^1 is a (1-6C)alkylthio group and wherein other variable groups are as defined in claim 1 and wherein any functional group is protected if necessary,

and thereafter

(i) removing any protecting groups; and

(ii) optionally forming a pharmaceutically-acceptable salt or in-vivo-cleavable ester.

Claim 10 **(previously presented)**: A pharmaceutical composition which comprises a pyrimidine compound of the Formula I, or a pharmaceutically-acceptable or in-vivo-cleavable ester formed from an available carboxy group thereof, as defined in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

Claims 11-14 **(cancelled)**.

Claim 15 **(presently amended)**: A method for inhibiting the production or effect of TNFα ~~TNF or IL-1~~ in a warm-blooded animal in need thereof comprising administering to said animal a TNFα ~~TNF or IL-1~~ inhibiting amount of a pyrimidine compound of the Formula I, or a pharmaceutically-acceptable salt or in-vivo-cleavable ester formed from an available carboxy group thereof, as defined in claim 1.

Claim 16 **(new)**. A method for the treatment of rheumatoid arthritis in a warm-blooded animal in need thereof comprising administering to said animal an effective amount of a pyrimidine compound of the Formula I, or a pharmaceutically-acceptable salt or in-vivo-cleavable ester formed from an available carboxy group thereof, as defined in claim 1.